Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:

NCT ID: NCT03639181 Recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)

Start date: October 15, 2018
Phase: Phase 2
Study type: Interventional

An open-label, single-arm, phase II clinical study of anti-PD-1 antibody GB226 in treatment of recurrent or refractory B-cell non-Hodgkin's lymphoma (B-NHL)

NCT ID: NCT03598608 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

Start date: October 17, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of favezelimab (MK-4280) in combination with pembrolizumab (MK-3475) using a non-randomized study design in participants with the following hematological malignancies: - classical Hodgkin lymphoma (cHL) - diffuse large B-cell lymphoma (DLBCL) - indolent non-Hodgkin lymphoma (iNHL) This study will also evaluate the safety and efficacy of pembrolizumab or favezelimab administered as monotherapy in participants with cHL using a 1:1 randomized study design. The study will have 2 phases: a safety lead-in and an efficacy expansion phase. The recommended Phase 2 dose (RP2D) will be determined in the safety lead-in phase by evaluating dose-limiting toxicities. There is no primary hypothesis for this study.

NCT ID: NCT03588598 Recruiting - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies

Start date: September 7, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of SHC014748M in patients with relapsed or refractory indolent B-cell hematologic malignancies.

NCT ID: NCT03579082 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma

Start date: June 1, 2018
Phase: Phase 4
Study type: Interventional

To explore the safety, tolerability and clinical effects of decitabine combined with R±DHAP for patients with replase and refractory Diffuse Large B cell lymphoma.

NCT ID: NCT03576807 Recruiting - Clinical trials for Relapsed or Refractory B-cell Lymphomas

The Clinical Research of Anti-CD20 CAR-T Cells in Patients With Refractory or Relapsed B Lymphocyte Lymphoma

Start date: April 4, 2018
Phase: Phase 1
Study type: Interventional

The present study is an exploratory study. Patients who meeting the enrollment conditions for relapsed or refractory B-cell lymphoma receive a single intravenous dose of CD20-CART cells. The research with the open-label, single arm running control methods in order to initially observe the safety, tolerability, and cellular pharmacokinetics of CD20-CART cell drugs.

NCT ID: NCT03571568 Recruiting - Clinical trials for Indolent B-Cell Non-Hodgkin Lymphoma

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

Start date: May 16, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

NCT ID: NCT03569696 Recruiting - Lymphoma, B-Cell Clinical Trials

Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy

NivoM
Start date: October 8, 2018
Phase: Phase 2
Study type: Interventional

This trial is designed as a unicenter, single arm phase II trial. The aim of the trial is to test whether prognosis of high-risk Aggressive B cell Lymphoma (ABCL) patients who are in complete remission (CR) post immunochemotherapy can be improved by 2year nivolumab maintenance therapy. Participants will be recruited from Chaim Sheba Medical Center as well as from other medical centers in Israel through the Israeli lymphoma group. Therapy will be treated in Chaim Sheba Medical Center.

NCT ID: NCT03564977 Recruiting - Lymphoma, B-Cell Clinical Trials

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Start date: July 15, 2018
Phase: N/A
Study type: Interventional

The main purpose of this study is to explore the efficacy of CD19-targeted CAR-T cell therapy for minimal residual disease (MRD) in B-cell Malignancies after autologous stem cell transplantation.

NCT ID: NCT03540303 Recruiting - Clinical trials for Relapsed Non Hodgkin Lymphoma

Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

Start date: April 12, 2018
Phase: Phase 1
Study type: Interventional

Evaluation of the safety and efficacy of CAR19 T cells carrying cytoplasmic activated PD1 in patients with refractory relapsed B-cell lymphoma

NCT ID: NCT03513601 Recruiting - Clinical trials for Diffuse Large B Cell Lymphoma

Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma

Start date: July 1, 2017
Phase: Phase 4
Study type: Interventional

To explore the clinical features and efficacy evaluation of large b-cell lymphoma in old age.